Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour.
Department of Medicine, Sarcoma Group, Institut Gustave Roussy, Villejuif, France.
Julien
J
Domont
Christophe
C
Massard
Nathalie
N
Lassau
Jean-Pierre
JP
Armand
Axel
A
Le Cesne
Jean-Charles
JC
Soria
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use*; D017809:Fatal Outcome; D005260:Female; D006393:Hemangiopericytoma / Q000098:blood supply* / Q000000981:diagnostic imaging / Q000188:drug therapy; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000000981:diagnostic imaging / Q000188:drug therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000627:therapeutic use*; D011758:Pyrroles / Q000627:therapeutic use*; D012008:Recurrence; D054364:Solitary Fibrous Tumors / Q000098:blood supply* / Q000000981:diagnostic imaging / Q000188:drug therapy*; D000077157:Sorafenib; D000077210:Sunitinib; D014057:Tomography, X-Ray Computed; D014463:Ultrasonography
D020533:Angiogenesis Inhibitors; D001557:Benzenesulfonates; D007211:Indoles; D010671:Phenylurea Compounds; D011725:Pyridines; D011758:Pyrroles; D009536:Niacinamide; D000077157:Sorafenib; D000077210:Sunitinib